TheraRadar
← Back
Data updated: Mar 29, 2026

COLLEGIUM PHARM INC

Neurology
Specialty

COLLEGIUM PHARM INC is a specialty pharmaceutical company focused on Neurology. Key products include NUCYNTA ER.

2008
Since
3
Drugs
-
Trials
11
Approved (2yr)

Key Drugs

NUCYNTA ER
tapentadol hydrochloride
Pain
MOR 3 indications · 2011
XTAMPZA ER
oxycodone
Pain
Mu opioid receptor 1 indications · 2016

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

NUCYNTA ER 2025-12-22
Labeling
XTAMPZA ER 2025-12-22
Labeling
NUCYNTA 2025-12-22
Labeling
NUCYNTA 2025-12-22
Labeling
NUCYNTA ER 2024-10-31
REMS
XTAMPZA ER 2024-10-31
REMS
NUCYNTA 2024-10-31
REMS
NUCYNTA 2024-10-31
REMS
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 100%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

AbbVie big-pharma
Neurology
GSK big-pharma
Neurology
Eli Lilly big-pharma
Neurology
Roche big-pharma
Neurology
Bristol-Myers Squibb big-pharma
Neurology